Caplin Point Laboratories Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by P Vijayalakshmi, was filed 23 Mar 2023.
Caplin Point Laboratories Limited: what insiders have been doing
Caplin Point Laboratories Limited, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEBI (PIT + SAST). No insider at Caplin Point Laboratories Limited has published a filing in the past twelve months. The most recent one dates from 23 March 2023.
Other companies in the same sector with recent insider buying flagged by our signals: Relmada Therapeutics, Inc. and MAIA Biotechnology, Inc. Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
Since the insiders bought
- +112.3%Entry ₹597.60 · Close at T+365 ₹1,268.70
- -11.7%Entry ₹836.10 · Close at T+365 ₹738.25
- -11.7%Entry ₹836.10 · Close at T+365 ₹738.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Caplin Point Laboratories Limited Strong Buy (bullish), based on 2 analysts. Average price target: ₹2,505.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 898,790 shares@ ₹609.00100.0% of flowEquity SharesSEBI:a7c7bfbdceae73f808ad695d9441c011dbe61979Canonical exit: 21 Jun 2023 (T+90)
- 5,000 shares@ ₹811.51299.8% of flowEquity SharesSEBI:b6d9f3372335b6b55772ea230796524513afd346
- 2,000 shares@ ₹832.0039.6% of flowEquity SharesSEBI:ad45f2e6ee8a5937b5b76c6f87a96010844778ca
- 1,500 shares@ ₹831.0029.6% of flowEquity SharesSEBI:f54cfffb98ca63f9856c475dbe7ec78c0a856a4f
- 1,500 shares@ ₹866.0530.8% of flowEquity SharesSEBI:e5dff0f2cd53e9dbad40acacdc92b191a73476d7
- 4,900 shares@ ₹867.7597.8% of flowEquity SharesSEBI:f4405800bcd1070b9c47b2b73aa68c2fc2387897
- 100 shares@ ₹870.002.0% of flowEquity SharesSEBI:e7290a6f4ccf206565c7dce9c837467879210bfb
- 3,333 shares@ ₹2.00100.0% of flowEquity SharesSEBI:7cc853f2c8407614cdd06a1e3a71bc0764cc9267Canonical exit: 31 Jan 2022 (T+90)
- 4,167 shares@ ₹2.00100.0% of flowEquity SharesSEBI:43b7e0cc72e5556b872565a5595c2eb63648ed02Canonical exit: 31 Jan 2022 (T+90)
- 1,667 shares@ ₹2.00100.0% of flowEquity SharesSEBI:c94350352e2ac74eff294a2a7e99456189214811Canonical exit: 31 Jan 2022 (T+90)
- 3,125 shares@ ₹2.00100.0% of flowEquity SharesSEBI:829ab7dd658eded031138d1b5ea7194082406812Canonical exit: 31 Jan 2022 (T+90)
- 10,000 shares@ ₹2.00100.0% of flowEquity SharesSEBI:10c3d008842ced8d9a8b9c06fe16f3e69ee7cf0eCanonical exit: 31 Jan 2022 (T+90)
- 2,500 shares@ ₹2.00100.0% of flowEquity SharesSEBI:c7d5a7c8fe3007977a76b43fd22250426a9775b3Canonical exit: 31 Jan 2022 (T+90)
- 1,667 shares@ ₹2.00100.0% of flowEquity SharesSEBI:4d5fef406eeee19ba20142a8633a3bbe0d3977ccCanonical exit: 31 Jan 2022 (T+90)
- 5,000 shares@ ₹2.00100.0% of flowEquity SharesSEBI:6b1ca4f13827dd8331647c1341a70f0231fd5af7Canonical exit: 31 Jan 2022 (T+90)
- 5,000 shares@ ₹2.00100.0% of flowEquity SharesSEBI:cb884ca0ee7c3a2db0be6e5df704b6f75bd71cc8Canonical exit: 31 Jan 2022 (T+90)
- 4,167 shares@ ₹2.00100.0% of flowEquity SharesSEBI:fee8bde8695372dae0faf696f505bd89a94855d1Canonical exit: 31 Jan 2022 (T+90)
- 5,000 shares@ ₹2.000.2% of flowEquity SharesSEBI:0e2d6fb71780554f0883e397b3ae72e6310fe547Canonical exit: 31 Jan 2022 (T+90)
- 3,333 shares@ ₹2.00100.0% of flowEquity SharesSEBI:91fd2c615d7be3f5aef1fc3189f0e11b7322718eCanonical exit: 31 Jan 2022 (T+90)
- 1,667 shares@ ₹2.00100.0% of flowEquity SharesSEBI:3881451dbcbe22e6be19fe68059d7d01966facbcCanonical exit: 31 Jan 2022 (T+90)
- 8,333 shares@ ₹2.00100.0% of flowEquity SharesSEBI:6e68ca78914a300dec36065b80d0a4fc72d065b9Canonical exit: 31 Jan 2022 (T+90)
- 3,333 shares@ ₹2.00100.0% of flowEquity SharesSEBI:217714239606b06299d8654f10eb315c2103d405Canonical exit: 31 Jan 2022 (T+90)
- 2,500 shares@ ₹2.00100.0% of flowEquity SharesSEBI:cbf7b5628d528d65c498e37cbc4719df6c0c318aCanonical exit: 31 Jan 2022 (T+90)
- 5,500 shares@ ₹2.00100.0% of flowEquity SharesSEBI:3084a17e41374f1a93444e951aa301c6b90c2f50Canonical exit: 31 Jan 2022 (T+90)
- 5,000 shares@ ₹2.00100.0% of flowEquity SharesSEBI:2a7dd5795aa38b13e956e43a34baef7a4778be7fCanonical exit: 31 Jan 2022 (T+90)
25 of 38 declarations
About Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is a pharmaceutical company specializing in the manufacture of generic drugs and injectable formulations. It is listed on the XBOM market.
